One marijuana stock expert thinks the market is settling on traditional metrics to evaluate companies in the space following a punishing set of summer months.

As the summer nears its end, the Investing News Network (INN) caught up with Greg Taylor, chief investment officer with Purpose Investments, to discuss the most recent quarterly earnings season and how investors are maturing alongside the marijuana space.

Read on to find out about why Taylor thinks cannabis investing is becoming more difficult as part of this maturity process.

Cannabis industry focusing on “normal metrics”

After extended hype and promotion around marijuana stocks, Taylor said he is seeing a direct shift into valid metrics that can properly capture the growth and development of these companies.

“After many years where everyone was just focusing on big growth plans and putting out flashy press releases, it now seems to be a switch to coming back to operating numbers; we’re focusing more on the cost of sales, we’re talking about normal metrics,” the executive told INN.

Taylor also acts as one of the portfolio managers of the Purpose Marijuana Opportunities Fund (NEO:MJJ).

He explained investors are moving towards only getting influenced by results and performance, a change that Taylor said is welcome in the Canadian cannabis investment market.

“I think (that’s a) big shift that had to come to the sector and it seems like it’s finally here in the Canadian investor,” he said.

As this maturity continues to spread across the Canadian cannabis stock market, the expert said it’s making it more difficult to invest in these names.

“For awhile, I think we were in a phase where people were still excited about the entire sector … you could almost buy any of these companies (and) they would go up and you would be able to make money on them,” Taylor told INN.

“Now that seems to (be) changing … we’re getting a big differentiator between the winners and losers, and the reality is there’s way too many companies in the sector.”

Consolidation in the cannabis market?

When asked if he expects to see shutdowns of existing marijuana companies in Canada, Taylor said he views the market as having no need for this many existing companies.

He anticipates that public companies will survive based on servicing niches that can appeal to investors.

Taylor said he has noticed investors are adding geographic diversity to their investments with regions including the US, Europe and even Asia.

Taylor further noted that the reason investors are looking abroad at some of the emerging companies there is because they offer the potential for a bigger market share and less competition.

However, the portfolio manager said he does not think investors need to completely abandon the Canadian cannabis play.

“Canada got a lot of investor attention because we were the first market to open up; that was unique, and when you have a unique opportunity you get a scarcity premium,” he said.

In short, Taylor is not ready to give up on the Canadian cannabis market, but he is asking for investors to diversify their marijuana portfolios and look at different geographies.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less